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Abstract 
Affective disorders are common comorbidities of chronic inflammatory pain that are often 
overlooked in primary care. As the impact of inflammatory pain upon mood-like disorders in 
animal models is not well known, our objective was to assess whether prolonged experimental 
monoarthritis (ARTH) induced the development of anxiety and depressive-like behaviours in 
rodents and if amitriptyline, an antidepressant commonly used in the treatment of chronic 
pain, could reverse both nociceptive and mood-like impairments. Experimental ARTH was 
induced through an injection of kaolin/carrageenan into the right knee joint with control 
(SHAM) animals injected with saline. Four weeks after induction, ARTH animals displayed 
mechanical hyperalgesia and a depressive-like phenotype as they showed a significant increase 
in immobility and a decrease in the latency to immobility in the forced-swimming test at the 
expense of the time spent climbing/swimming. ARTH animals also displayed a decreased 
sucrose preference, an index of anhedonia and anxiety-like behaviour as time spent exploring 
the open arms of the elevated-plus-maze was decreased when compared to controls. The 
anxiety-like phenotype was also supported by an increase in the number of fecal boli left in the 
open field. In ARTH animals, the administration of amitriptyline decreased mechanical 
hyperalgesia and increased sucrose preference and the time spent climbing, although it had a 
deleterious effect in the performance of control animals. Our data show that this model of 
ARTH can be useful for the study of chronic pain-mood disorders comorbidities and that 
amitriptyline is able to partly reverse the associated nociceptive and emotional impairments. 
Keywords: Experimental monoarthritis, Pain-mood disorders comorbidity, Mechanical 
hyperalgesia, Amitriptyline.  
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1. Introduction  
Joint pain is a condition that affects millions of people, especially the elderly, representing a 
huge burden on National Health Programs [1]. Pain is the most common complaint in arthritis 
but often patients exhibit clinical signs of comorbid depression and anxiety [2] that frequently 
go untreated [3]. 
Curiously, although many animal models of chronic inflammatory pain are available and 
extensively used, only a few studies addressed inflammatory pain and mood disorders 
comorbidity [4,5,6,7]. However, the animal models and time points chosen to perform the 
behavioural analysis are different among studies. For example, the time frame of osteoarthritis 
(OA) settlement is one feature of the behavioural experimental designs that could by itself 
limit the full development of neuropsychological impairments (anxiety- and depressive-like 
behaviour) in a slow developing disease such as OA. Accordingly, recent data obtained from 
studies on chronic neuropathy [8] demonstrated that the experimental time frame adopted is 
critical to model the affective pathologies associated to chronic pain. These authors showed 
that anxiety and depressive-like behaviours developed in a time-dependent manner, with the 
former present at three weeks of neuropathy while the latter was expressed only after 6 
weeks of neuropathy. 
In spite of all the evidence demonstrating the existence of pain-depression comorbidity, the 
actual mechanisms underlying this interaction are still mostly unknown [3]. While chronic pain 
patients are up to four times more prone to develop major depressive disorders than the 
general population [9], more than half of depressed patients present comorbid chronic pain 
[8], with the effects of having both chronic pain and depression being worse than suffering 
from chronic pain or depression alone [10]. Therefore, antidepressants, including tricyclic 
antidepressants (TCAs), are extensively used in the management of both chronic pain and 
depression [11]. TCAs are the first-line drugs for the treatment of chronic pain and 
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amitriptyline (AMI), the most commonly used TCA to treat depression in chronic pain patients 
[12], has also been associated with significant analgesia in different animal models of chronic 
neuropathic pain [13]. 
Accordingly, in the work herein, we used the kaolin/carrageenan model of experimental knee 
monoarthritis (MA) to establish a direct link between prolonged MA and the development of 
mood-like disorders in rodents. After four weeks of MA, we treated the animals with AMI to 
evaluate whether this antidepressant could reverse the nociceptive and mood-like changes 
induced by the model. 
 
2. Materials and methods 
2.1. Animals and ethical questions 
The experiments were performed in adult male Wistar rats (n=44, Charles Rivers, Barcelona, 
Spain) weighting 225–250g at the beginning of the experiment. The experimental protocol was 
approved by the Institutional Ethical Commission and followed the European Community 
Council Directive 86/609/EEC and 2010/63/EU concerning the use of animals for scientific 
purposes. All efforts were made to minimize animal suffering and to use only the number of 
animals necessary to produce reliable scientific data. 
Animals were housed in pairs under a 12h light cycle (starting at 8:00 a.m.) with food and 
water available ad libitum. General health parameters were surveyed twice per week by the 
resident veterinary and animal weight was recorded every week throughout the experimental 
period. Before the beginning of the experiment, all animals were handled daily by the 
experimenter for a week and on the day of the experimental sessions animals were left in the 
experimental room for an hour in order to habituate to the surroundings. 
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2.2. Induction of monoarthritis 
The induction of arthritis (ARTH) was performed as described in detail elsewhere [14]. Briefly, 
3% kaolin and 3% carrageenan (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in distilled 
saline solution (0.9% NaCl) and injected into the synovial cavity of the right knee joint at a 
volume of 0.1 mL. This model produces mechanical hyperalgesia, which begins just in a few 
hours after surgery and lasts for several weeks [15]. Control animals (SHAM) were injected 
with 0.1 mL saline in the synovial cavity of the right knee joint. 
2.3. Behavioural assessments 
2.3.1. Nociceptive behaviour 
In each animal, the development of arthritis was verified 1–2 h prior to each experiment. Only 
those rats that vocalized every time after five flexion–extension movements of the knee joint 
were considered to have developed osteoarthritis, and were included in the ARTH group. 
SHAM animals did not vocalize to any of the five consecutive flexion–extension movements of 
the knee joint. 
2.3.1.1. Pressure Application Measurement 
The application of noxious pressure to the primary site of injury is a classical approach to 
measure mechanical hyperalgesia [16], both in humans and animals [17]. Here, a new pressure 
application measurement (PAM) method was used. It allows an accurate behavioural 
measurement of primary mechanical hypersensitivity in rodents with chronic inflammatory 
joint pain [18] by the application of a force range of 0–1500g. To perform the test and with the 
animal securely held, the force transducer unit (fitted to the experimenter’s thumb) is placed 
on one side of the animal's knee joint and the forefinger on the other and an increasingly force 
is gradually applied across the joint until a behavioural response is observed (paw-withdrawal, 
freezing of whisker movement, wriggling or vocalization) with a cut-off of 5s. The peak force 
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(in grams force (gf)) applied immediately prior to the behavioural response is recorded as the 
limb withdrawal threshold (LWT). LWT was measured twice in both the ipsilateral and 
contralateral limbs at 1 min intervals. The mean LWTs were calculated per animal. At the end 
of the session animals were returned to their home cage. 
2.3.2. Locomotor activity and anxious-like behaviour 
2.3.2.1. Open-field test 
The open field (OF) test was used to evaluate differences in the locomotor ability between 
SHAM and ARTH animals and followed a protocol previously implemented in our lab [19]. In 
summary, locomotor behaviour was assessed by measuring the total distance travelled by the 
animal inside the arena and anxiety-like behaviour was evaluated through the analysis of the 
time spent in the centre of the arena and by counting the number of faeces (fecal boli) 
remaining in the arena at the end of each trial [20]. The OF test was performed in a square 
arena (43.2 cm wide with the central area of the arena corresponding to a square 21.6cm wide 
and equidistant from the borders) with transparent acrylic walls (Med Associates Inc., St. 
Albans, Vermont, USA) in a brightly illuminated room (240 lux in the centre of the arena). The 
test started when the animal was placed at the centre of the arena and its exploratory activity 
was automatically registered during 5 min. The arena was cleaned with 10% alcohol between 
each trial.  
2.3.2.2. Elevated-plus maze 
The elevated-plus maze (EPM) was used to assess anxiety-like behaviour and followed a 
protocol previously implemented in our lab [21]. The EPM apparatus (ENV-560; 
MedAssociates, St. Albans, Vermont, USA) consisted of two opposite open arms (50.8 × 10.2 
cm) and two closed arms (50.8 × 10.2 × 40.6 cm), which were elevated 72.4 cm above the 
floor. At the beginning of the test the animal was placed in the centre of the maze and allowed 
5 min to freely explore the maze. During the duration of the trial, behaviour was recorded 
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through the use of an infra-red photobeam system connected to a computer with software 
(MedPCIV, MedAssociates) that allows for the quantification of the time spent in each arm. 
Between trials, the maze was cleaned with 10% ethanol. The percentage of time spent in the 
open arms was used as an index of anxiety-like behaviour. 
2.3.3. Depressive-like behaviour 
2.3.3.1. Sucrose preference test 
Anhedonia, measured as a reduction in sucrose preference (SPT), was assessed through the 
application of a protocol adapted from Bessa et al. [21]. This protocol includes an initial 
exposure of the animals to the sucrose solution a week before the induction of ARTH. During 
this session, performed during their active period (8:00 p.m.), animals (without any previous 
water and food restriction) had free access to both water and the sucrose solution for 2h. In 
addition, the behaviour of the animals was monitored by the experimenter in order to certify 
that all animals tasted the sucrose solution. On the test day and after twenty-four hours of 
food/water deprivation, each animal was presented with two pre-weighted bottles [water and 
sucrose solution (2%)] for one hour (8:30-9:30p.m). Afterwards, the bottles were re-weighted 
and sucrose preference was calculated using the equation:  
Sucrose_preference=[sucrose_intake/(sucrose+water)_intake]×100. 
For experiment 1, the results are presented as the difference in sucrose preference between 
the data obtained at four weeks post-ARTH induction and the basal assessment that preceded 
the induction of monoarthritis. In experiment 2, the results are presented as the difference in 
sucrose preference between the data obtained during the fourth week of pharmacological 
treatment and the assessment performed at four weeks post-ARTH induction. 
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2.3.3.2. Forced swimming test 
Learned helplessness was evaluated in the modified forced-swimming test (FST) [22] and 
followed a protocol previously implemented in our lab [21]. Animals were submitted to a pre-
test session (10 min) in which they were individually placed in cylinders filled with water (25°C; 
depth 30 cm). Twenty-four hours later animals were again placed in the cylinders for a period 
of 5 min and the testing session was recorded with a video camera. The quantification of (i) 
latency to immobility, (ii) time spent immobile, (iii) time spent swimming and (iv) time spent 
climbing was performed by a blind observer that rated the videos using the Etholog software 
[23]. Note that the time spent swimming and climbing was discriminated as opposed to 
floating as previously described by Rénéric and colleagues (2002) [24]. Learned helplessness 
behaviour was defined as an increase in time of immobility at the expense of the time spent 
swimming /climbing and a decrease in the latency to immobility. 
2.4. Drug treatment 
Four weeks after arthritis induction, amitriptyline hydrochloride (AMI; Sigma-Aldrich, St. Louis, 
MO, USA) was dissolved in saline (SAL) and administered intraperitoneally (i.p.) at a dose of 
15mg/kg daily for three weeks, until the beginning of the behavioural tests. The 
pharmacological treatment with AMI or SAL was maintained during the duration of the 
behavioural evaluation with injections being administered daily at the end of the behavioural 
session. 
2.5. Experimental design 
The present study was divided in two main experiments (Fig. 1A), (i) the first one involving the 
assessment of the comorbid development of mood-like disorders in animals with experimental 
ARTH and (ii) the second determining the potential of amitriptyline in reversing both the 
nociceptive and the emotional-like components of chronic experimental ARTH. 
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In experiment 1, one week preceding the intrasynovial injection animals were presented to a 
sucrose solution and in the day before knee injection animals were submitted to a baseline 
evaluation in the sucrose preference test (SPT).  After four weeks of the knee injection animals 
were tested in the SPT, PAM, OF, EPM and FST. At the end of the behavioural sessions animals 
were sacrificed with a lethal dose of pentobarbital and the knee joints were removed for 
further histological processing and analysis.  
In experiment 2, one week preceding the intrasynovial injection animals were presented to a 
sucrose solution and in the day before the beginning of the treatment animals were submitted 
to a baseline evaluation in the sucrose preference test (SPT).  After four weeks of the 
intrasynovial injection SHAM and ARTH animals were administered either saline (SHAM_SAL 
and ARTH_SAL) or amitriptyline (SHAM_AMY and ARTH_AMY). Three weeks after the 
beginning of the treatment, animals were behaviourally tested following the same 
experimental design as in experiment 1 (Fig. 1A). 
2.6. Histology 
Right knees from SHAM and ARTH animals were excised and fixed in paraformaldehyde 
solution (4%). Knees were subsequently submerged in a decalcifying solution (BiodecR, Bio-
Optica, Milan, Italy) for 48 hours, paraffin embedded, cut into 4-µm sections and stained with 
hematoxylin and eosin (Fig. 1B). 
2.7. Statistical analysis 
The GraphPad Prism® 6 software (GraphPad Software Inc, La Jolla, CA, USA) was used to 
perform the statistical analysis.  Differences in weight gain between ARTH and SHAM groups 
were evaluated by applying a mixed-design two-way analysis of variance (ANOVA) followed by 
t-test with a Bonferroni correction for multiple comparisons. The comparisons of differences 
between groups in experiment 1 were performed using a Student’s t-test for unpaired data. A 
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two-way ANOVA followed by t-test with a Bonferroni correction for multiple comparisons was 
used to compare results from the behavioural assessment at the end of experiment 2, except 
for the PAM test where a repeated measures two-way analysis of variance followed by t-test 
with a Bonferroni correction for multiple comparisons was performed. Statistical significance 
was accepted for P<0.05. Data in the results section are expressed as mean ± standard 
deviation (SD). 
 
3. Results 
3.1. Body weight 
In experiment 1, body weight of all animals increased significantly (main effect of elapsed time: 
F4,40=136.00, P<0.001) but ARTH animals gained less body weight during the experimental 
period than SHAM animals (interaction between elapsed time and the experimental group: 
F4,40=3.16, P=0.024). In experiment 2, the administration of AMI induced an overall 10% 
decrease in the body weight of SHAM and ARTH animals when compared with SAL-treated 
animals (interaction between weight gain and experimental group during AMI treatment: 
F9,112=20.68, P<0.001). 
3.2. Nociceptive Behaviour  
All animals in the ARTH group developed a clear swelling of the treated knee joint and all gave 
a vocalization response during a minor extension and flexion of the affected limb. SHAM 
animals displayed no obvious swelling of the knee joint and did not vocalize when the limb was 
flexed. 
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3.3. Histological analysis 
As shown in figure 1-B1, SHAM animals presented no surface abnormalities in the joint. In 
ARTH animals an overall tissue degeneration is evident with the medial femoral plateaux (FP) 
being more affected than the tibial plateaux (Fig. 1-B2). In the FP it is possible to observe focal 
damage of cartilage surface associated to a decrease in cartilage thickness in the central area, 
reduplication of the tidemark and some surface fibrillation. Additionally, there is an increase in 
subchondral bone volume concomitant with subchondral sclerosis, decreased bone marrow 
area and subchondral cyst formation. 
3.4. Experiment 1 
3.4.1. Mechanical hyperalgesia 
LWT was significantly decreased in ARTH animals compared to SHAM (t10=4.885, P<0.001) 
confirming their arthritic state (Fig. 2A). 
3.4.2. Locomotor activity 
In the OF test, total distance travelled by the animals was not different between SHAM and 
ARTH animals (t10 = 0.790, P=0.448) (Fig. 2B). 
3.4.3. Anxiety-like behaviour 
In the OF, ARTH animals showed a strong tendency to spend less time in the centre of the 
arena (t10=2.122, P=0.060) (Fig. 2C) and left a significantly higher number of fecal boli in the OF 
arena (t10=3.078, P=0.012) (Fig. 2D) when compared to SHAM animals, indicating they 
developed an anxious-like phenotype. This was confirmed in the EPM test, as ARTH animals 
also spent less time in the open arms (t10=2.665, P=0.024) (Fig.2E). 
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3.4.4. Depressive-like behaviour  
ARTH animals displayed a depressive-like phenotype as these animals showed a significantly 
decreased preference for sucrose solution (i.e., anhedonia-like behaviour) when compared 
with the SHAM group (t10=2.319, P=0.043) (Fig. 2F). No differences in liquid consumption per 
body weight unit were found between the experimental groups (t10=1.755, P=0.110). SPT 
results are further substantiated in the FST where ARTH animals showed a significant decrease 
in the latency to immobility (t10=2.845, P=0.017) (Fig. 3A). This finding was accompanied by an 
increase in the immobility time (t10=3.630, P=0.005) (Fig. 3B) and a corresponding decrease of 
the time spent swimming (t10=2.955, P=0.014) (Fig. 3C) and climbing (t10=3.267, P=0.009) (Fig. 
3D) by ARTH animals. 
3.5. Experiment 2 
3.5.1. Mechanical hyperalgesia after treatment 
LWT was significantly different between the experimental groups (main effect of the 
experimental group: F1,28=12.310, P=0.002) with ARTH animals displaying a lower LWT when 
compared to SHAM animals (data not shown). Additionally, LWT also varied with the drug 
treatment (interaction between the experimental group and drug treatment: F1,28=7.565, 
P=0.010) since ARTH animals treated with AMI displayed a higher LWT when compared to 
ARTH treated with SAL. Post hoc tests showed that AMI was able to reverse primary 
hyperalgesia as shown by the increase in LWT of ARTH_AMI animals to the level of SHAM 
animals (Fig.4A). 
3.5.2. Locomotor activity 
In the OF test, total distance travelled by the animals was not different between experimental 
groups (main effect of test group: F1,28=0.618, P=0.438) (Fig. 4B). 
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3.5.3. Anxiety-like behaviour after treatment 
In the OF test, there were no differences in the time spent in the centre of the arena (main 
effect of test group: F1,28=2.405, P=0.1322) (Fig. 4C). The number of fecal boli that remain in 
the OF arena varied with the drug treatment (interaction between the experimental group and 
drug treatment: F1,28=7.488, P=0.011) (Fig. 4D). In the EPM there were no significant 
differences between the groups in the time spent in the open arms (main effect of test group: 
F1,28=1.348, P=0.256) (Fig. 4E). Note that SHAM_AMI animals had behavioural performances 
similar to ARTH_SAL animals (Fig. 4). 
3.5.4. Depressive-like behaviour after treatment 
Sucrose preference was significantly different between the experimental groups (main effect 
of test group: F1,28=5.536, P=0.026) with SHAM animals displaying more preference for the 
sugary beverage when compared to ARTH animals. Additionally, sucrose preference also varied 
with the drug treatment (interaction between group and drug: F1,28=6.044, P=0.020) since 
ARTH animals treated with AMI consumed considerably more sucrose than ARTH animals 
treated with SAL. Post hoc tests confirm that ARTH_AMI animals increased sucrose preference 
when compared with ARTH_SAL animals (Fig. 4F). In the FST, the latency to immobility 
between the groups varied with the drug treatment (interaction between the group and drug: 
F1,28=6.710, P=0.015) as SHAM and ARTH animals treated with AMI display a lower latency to 
immobility. Post hoc tests indicated that the latency to immobility was significantly shorter in 
the SAL-treated ARTH than SHAM group and also between SAL-treated SHAM and AMI-treated 
SHAM (Fig. 5A). The duration of the immobility time was significantly different between 
treatments (main effect of test drug: F1,28=5.303, P=0.029) as SHAM animals treated with AMI 
increased the amount of immobility time. In parallel, the difference in the immobility time 
between the groups varied with the drug treatment (interaction between group and drug: 
F1,28=6.801, P=0.015) as ARTH animals treated with AMI showed no difference in immobility 
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time while SHAM treated with AMI significant increased the time spent immobile. Post hoc 
tests confirm that the duration of immobility time was significantly longer in the SAL-treated 
ARTH than SHAM group (Fig. 5B). Concerning the duration of the active period, the time spent 
swimming was significantly different between the experimental groups (main effect of the 
group: F1,28=5.658, P=0.024) since ARTH animals spent less time swimming when compared to 
SHAM. In addition this parameter also varied with the treatment (main effect of the drug: 
F1,28=15.470, P<0.001) since the time spent swimming was decreased in SHAM animals after 
the treatment with AMI when compared with SAL-treated SHAM. Moreover, the difference in 
swimming time between the groups was dependent on the drug treatment (interaction 
between the group and drug: F1,28=5.198, P=0.030) since the effects of AMI administration 
were restricted to SHAM animals. Post hoc tests confirm that the swimming time was shorter 
in the SAL-treated ARTH than SHAM group (Fig. 5C).  
The difference in time spent climbing varied with the drug treatment and the experimental 
group (interaction between the group and drug: F1,28=14.800, P<0.001) since ARTH animals 
treated with AMI increased the time spent climbing while AMI-treated SHAM animals 
decreased it. Post hoc tests confirm that the duration of the climbing time was significantly 
longer in the AMI-treated ARTH than SHAM group (Fig. 5D). Overall, SHAM animals treated 
with AMI had behavioural performances similar to ARTH animals treated with SAL (Fig. 5). 
 
4. Discussion 
In this study, we demonstrate that the K/C animal model can be used as a valid method to 
study the comorbidity between arthritis and mood disorders in the rat. In addition to sustained 
hyperalgesia (decreased withdrawal threshold to noxious mechanical stimulation of the 
inflamed knee), animals with four weeks of K/C–induced arthritis exhibited anxiety-like 
behaviour (low exploratory activity in the EPM and increased defecation in the OF arena), 
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anhedonic behaviour (reduced preference for sucrose) and learned helplessness (decreased 
mobility in the FST). We also demonstrated that after three weeks of antidepressant 
treatment, AMI is able to decrease mechanical hyperalgesia and partly reverse depressive-like 
behaviour, as the preference for sucrose is increased in ARTH animals and they spend more 
time climbing in the forced swimming test. Due to the importance of using animal models that 
mimic the greatest number of features of the human disorders, we anticipate that the 
concomitant study of pain and emotional-like behaviours in the experimental model of 
arthritis will significantly increase our understanding of the mechanisms underlying 
comorbidity of chronic pain and mood disorders. 
In general K/C-induced arthritis has been established as model of acute monoarthritis that 
partly mimics the initial inflammatory stages of OA [25]. The advantage of also administering 
kaolin is the mechanical damage to intra-joint structures [26] triggered by this clay, which is 
absent in inflammatory models using carrageenan alone. Taking into account that 
inflammatory disorders are slowly progressing degenerative diseases it is most surprising that 
the majority of studies using this model use a restricted time frame (e.g. 4h [27], 5-6h [28] and 
1 week [29]). Our data contrast with most studies, reporting marked cellular infiltration, as we 
observe a clear degeneration of the femoral plateaux (thinning of the cartilage, fibrillation and 
subchondral sclerosis). This degree of joint degeneration partly mimics features of later stages 
of chronic inflammatory diseases, in particular of osteoarthritis. Indeed and according to 
Pearson’s [30] report, our animals display a knee joint degeneration level concomitant with 
stage three of human osteoarthritis that comprises the presence of deep fissures, loss of 
cartilage, remodelling of the bone plate and reduplication of the tidemark. Nonetheless, 
further studies involving a time dependent evaluation of the succession of events affecting 
knee joint structure are needed for this K/C-induced arthritis to be considered a valid 
osteoarthritis model. 
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Anxiety and depression [31] are important comorbidities that have been positively correlated 
with pain severity in arthritic patients. These mood disorders are 2 to 3 times more prevalent 
in OA patients than in patients with other chronic pathologies [3]. However, to date and to the 
best of our knowledge, only one experimental animal study [32] has addressed the 
comorbidity of pain and depression in OA, in spite of the availability of many animal models 
mimicking specific aspects of the OA pathology [33]. It should be emphasized that in our study 
anxiety- and depression-like behaviours were assessed after a sustained hyperalgesic state 
that had lasted 28 days, whereas the majority of the studies from other authors used more 
restricted time-frames (see above).  
Our data shows that ARTH animals with 28 days of the K/C-induced arthritis display a profound 
mechanical hyperalgesia in the ipsilateral knee (PAM test), which parallels the hyperalgesic 
response of OA patients to noxious stimulation of the knee [34]. Interestingly, some reports 
have positively associated motor disability with the development of depression in OA patients 
[31]. However, although our ARTH rats present mechanical hyperalgesia, they did not display 
any locomotor impairments as the total distance travelled in the OF was not different from 
SHAM animals. Hence, in this work the development of mood-like disorders could not be 
associated to locomotor disability of rodents. 
Clinical treatment of joint disorders focuses mainly on ameliorating pain and functional 
limitations [35], while less attention is paid to mood comorbidities [2]. However, several 
studies have shown that the prevalence of anxiety and depression e.g. in OA patients is very 
high [2,31], around 41% and 62%, respectively, although the recognition of both depression 
and anxiety in primary care settings is typically lower, less than 50% [2]. Similarly, in preclinical 
OA studies most authors have focused on acute changes in behaviour or molecular and cellular 
responses [4-7,27-29,36,37]. In experimental animal studies on neuropathic pain, comorbid 
anxiety- and depression-like behaviour has been studied more extensively. For example, Yalcin 
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et al.[8] assessing anxiety and depression-related behaviours in a mouse model of neuropathic 
pain demonstrated a time-dependent development of mood-like disorders. Their findings 
indicate that anxiety-related behaviour was developed 4 weeks after induction of the 
neuropathy, whereas depression-related behaviours were observed 2-4 weeks later. 
In the currently used K/C model, the development of anxiety-like behaviour had already been 
shown by Ji et al. [28] as early as 24h after its induction. Using a similar set-up, we 
demonstrated that ARTH animals still displayed anxiety-like behaviour at four weeks post-
induction as shown by the significant decrease in the time spent in the open arms of the EPM. 
In addition, ARTH animals also displayed an anxious-like phenotype in the open field test as 
this group left a significantly higher number of fecal boli in the OF arena when compared to 
SHAM animals. Despite its simplicity, defecation is considered an important indicator of 
emotional responses, particularly in anxiety-like behaviour [20]. 
While the results by Yalcin et al. [8] showed that the development of depression-like behaviour 
in neuropathic animals took 6-8 weeks, our results indicate that in the K/C model the 
depressive-like phenotype appeared earlier, at four weeks. This was shown by a decrease in 
the latency to immobility, an increase in the duration of immobility and a decrease in active 
behaviours (climbing and swimming) in the FST. This type of behavioural change in 
experimental animals is considered an index of learned helplessness that presumably 
represents human “resignation” [38]. Yet, based on studies on neuropathic pain by Wang et al. 
[39], it could be argued that the differences obtained between SHAM and ARTH animals in the 
FST could be explained by motor deficits of ARTH animals. However, ARTH animals of the 
present study failed to display any motor impairments in the OF. Nor could we detect any 
obvious difference in the use of the left and right hind paws during the FST. Moreover, the 
depressive-like phenotype obtained in the FST is further supported by the SPT data, a test that 
does not implicate/require motor coordination.  
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Although the analysis of anhedonia (lack of interest in pleasure) in rodents has to be 
approached with caution, a reduced preference for a sweet solution is considered to share 
some analogy with anhedonia and depressive behaviour in humans [40] and therefore, the SPT 
is widely used in stress studies [41]. Our ARTH animals showed a significant decrease in the 
preference for a sweet solution when compared to SHAM, hence displaying a clear hedonic 
deficit. It has been argued that sucrose intake can also be influenced by body weight [41], but 
comparing the ratio between animal body weight and liquid consumption between groups 
revealed no significant differences between ARTH and SHAM animals. This finding gives further 
support to the presence of an anhedonic state in ARTH animals.  
In what concerns the performance of AMI-treated SHAM animals, there appears to be an 
anxiogenic and pro-depressive effect of AMI on these animals as shown in the OF and the FST 
tests. In clinical practice, antidepressants are known to have deleterious effects when 
administered to non-depressed patients [42] comprising, amongst others, sedation, lower 
reaction time in the choice reaction time task, sensory impairments, disruption of 
discrimination ability, dry mouth, dizziness and constipation [42,43]. In what concerns the 
effects of prolonged AMI administration to animals only a few works reported frequency-
related depression of ventricular conduction in dogs [44,45]. Nonetheless, in a preliminary 
study (unpublished data) where we compared the motor performance of AMI- and SAL-treated 
SHAM animals in the Rotarod test (increasingly faster rotations) no differences could be found 
between experimental groups. These results are in accordance with a report from Bomholt et 
al. [46] also showing that the acute administration of AMI did not alter the motor performance 
of SHAM animals in the Rotarod test. Based on these results we considered that the 
detrimental effects of AMI administration to SHAM animals were not motor related. 
Recurrent episodes of inflammation at the damaged joints in arthritic patients lead to the 
release of inflammatory mediators that activate voltage-gated sodium channels causing 
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peripheral/central sensitization and ultimately, persistent inflammatory pain [47]. Descending 
monoaminergic pathways play an important role in inhibiting pain transmission at the spinal 
cord level [48]. Tricyclic antidepressants (TCAs), which inhibit the reuptake of serotonin and 
noradrenalin, are essential components of the current pain management therapeutic 
strategies in chronic pain disorders, including rheumatoid arthritis [49]. Yet, Richards et al. [49] 
while studying the effect of AMI in controlling pain in a data base of controlled trials in adults 
with rheumatoid arthritis or ankylosing spondylitis could not confirm the efficacy of this TCA as 
an analgesic. No available data could be found concerning the use of AMI for pain 
management in monoarthritic/osteoarthritic patients. Nonetheless, our data shows that the 
administration of AMI to ARTH animals significantly decreased mechanical hyperalgesia after 
three weeks of treatment. Interestingly, this effect might result not only from increased 
availability of brain serotonin and noradrenaline and subsequent activation of descending 
pathways as demonstrated in other works [48,50], but also from a peripheral effect as this 
drug decreases the activity of sodium and calcium voltage dependent channels [51]. This 
hypothesis is supported by demonstration that AMI selectively inhibits ectopic discharge of 
low frequency and bursting discharge in animal models of neuropathic pain [52], and that the 
antidepressants’ ability to block sodium channels could effectively suppress persistent 
peripheral signaling [53]. 
Although AMI had no effect upon anxiety-like behaviour, it efficiently reversed the hedonic-
like behaviour as measured in the SPT. These results are consistent with data from other 
studies showing that the decrease in depressive-like behaviour results from the modulation of 
the activity of serotonin transporters [54] and of several receptors [54,55]. However taking into 
account our results from the FST it is unlikely that the effect of AMI reported herein is related 
to the modulation of serotonin receptors, as no differences were found for the swimming 
component of the test, but rather to an effect of this drug on noradrenergic receptors. In fact, 
similarly to what was observed by Detke et al. [56], in rats injected with specific noradrenaline 
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uptake inhibitors, the administration of AMI to ARTH animals selectively increased climbing 
behaviour without altering the time spent swimming. 
 
5. Conclusions 
So far, it is not clear which components of chronic inflammation are directly involved in the 
development of mood disorders in human patients with an inflammatory joint disorder such as 
OA [57]. The causes of pain-depression comorbidity in patients with arthritis are complex 
(involving sensory, affective and cognitive processes) and the abnormal peripheral and central 
mechanisms of pain processing involved in this comorbidity are far from being understood. 
Our present results support the proposal that the K/C model in the rat provides a good pre-
clinical tool for studying the link between chronic inflammatory joint pain and mood disorders, 
as well as a model for testing novel drugs that may modulate pain intensity, mood disorders, 
or both. Importantly, AMI was able to reverse the nociceptive and hedonic components of 
chronic inflammatory pain with its influence likely due to a simultaneous combination of 
central and peripheral effects. 
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Figure Legends 
Figure 1. (A) Time course of the two main experiments, (i) the first one involving the 
assessment of the comorbid development of mood-like disorders in animals with experimental 
ARTH and (ii) the second that evaluated the potential of amitriptyline in reversing both the 
nociceptive and the emotional-like components of chronic experimental ARTH. One week 
preceding the intrasynovial injection animals were presented to a sucrose solution and in the 
day before the knee injection animals were submitted to a baseline evaluation in the sucrose 
preference test (SPT). Four weeks after the intrasynovial injection the first test performed was 
the SPT followed by 24h of rest to compensate for the fasting period. The next evaluation was 
the pressure application measurement (PAM), on day 3 followed by the open field test (OF) 
and elevated plus maze (EPM) on days 4 and 5, respectively. Finally, we opted to perform the 
forced swimming test (FST) in the last two days so that the physical effort associated to it 
would not bias the results of the other tests. In experiment 2, animals were divided into four 
experimental groups: SHAM animals that received saline (SHAM_SAL) or amitriptyline 
(SHAM_AMI) and ARTH animals that received saline (ARTH_SAL) or amitriptyline (ARTH_AMI). 
Four weeks after the intrasynovial injection animals were submitted to a baseline evaluation in 
the SPT followed by three weeks of daily injections of SAL or AMI. In the fourth week of the 
treatment, animals were behaviourally tested following the same experimental design as in 
experiment 1. (B) Sections of the femoro-tibial joint space stained with eosin-haematoxylin of 
SHAM and ARTH animals four weeks after the induction of arthritis. In SHAM animals (B1) the 
structure of the femoro-tibial joint is preserved (M: meniscus; PL: patellar ligament; FC: 
femoral condyle; TP: tibial plateau and SCB: subcondral bone). In ARTH animals (B2), cartilage 
damage (a) can be observed in addition to fibrillation and marked thinning of the central part 
of the articular surface. In the FC, subchondral sclerosis (c), cyst formation (d) and 
inflammation (infiltration of immune cells) (e) are present while in the TP only cyst formation 
(b) is observed at this time point. 
30 
 
Figure 2. Behavioural assessment four weeks after arthritis induction, in experiment 1. 
Evaluation of the right (ipsilateral) limb withdrawal latency (LWT) in the pressure application 
measurement (PAM). The LWT of arthritic (ARTH) group was significantly decreased when 
compared to results in control (SHAM) animals (mechanical hyperalgesia) (A). No differences 
were found in locomotor behaviour between arthritic (ARTH) and control (SHAM) groups, as 
indicated by the total distance travelled in the open field (OF) test (B). ARTH animals showed 
increased anxiety-like behaviour as indicated by: the tendency to avoid the centre of the OF 
arena (C); the significantly higher number of fecal boli left in the arena at the end of the trial 
(D); and the reduction in time spent in the open arms of the EPM test, when compared to 
SHAM animals (E). ARTH animals displayed an anhedonic-like behaviour as showed by the 
significant decrease in the preference for sucrose solution in the sucrose-preference test (SPT) 
(F) (Δ sucrose preference is the variation in sucrose preference between the data obtained 
four weeks after and one day before monoarthritis induction). Results are expressed as 
Mean+SEM (n=6 per group). *P<0.05, **P<0.01. 
Figure 3. Behavioural assessment in the forced swimming test (FST), in experiment 1. Four 
weeks after the induction of experimental arthritis, ARTH animals become immobile 
significantly earlier than SHAM animals in the forced swimming test (FST) (A). ARTH animals 
spent significantly more time immobile than SHAM animals (B), at the expense of the time 
spent swimming (C) and climbing (D) in the FST test. Results are expressed as Mean+SEM (n=6 
per group). *P<0.05, **P<0.01. 
Figure 4. Behavioural assessment after treatment with amitriptyline (AMI), in experiment 2. 
Evaluation of the right (ipsilateral) limb withdrawal latency (LWT) in the pressure application 
measurement (PAM). The LWT of arthritic (ARTH) animals treated with AMI increased when 
compared to ARTH animals treated with saline (SAL), reaching control (SHAM) levels (abolished 
mechanical hyperalgesia) (A). No differences were found in locomotor activity between 
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arthritic (ARTH) and control (SHAM) groups, as indicated by the total distance travelled  in the 
open-field (OF) test (B). ARTH animal treated with AMI showed no difference in anxiety-like 
behaviour when compared to ARTH animals treated with SAL in both the time spend in the 
centre of the OF arena (C) and the number of fecal boli (D). In the elevated plus maze (EPM) 
test no differences were observed in the time spent in open arms (E). In the sucrose 
preference test (SPT), ARTH animals treated with AMI increased sucrose preference when 
compared with ARTH animals treated with SAL (F) (Δ sucrose preference is the variation in 
sucrose preference between the data obtained three weeks after and one day before the 
beginning of the treatment). Results are expressed as Mean+SEM (n=8 per group). **P<0.01, 
***P<0.001. 
Figure 5. Behavioural assessment in the forced swimming test (FST) after treatment with 
amitriptyline (AMI), in experiment 2. AMI did not reverse the effect of arthritis on the latency 
to immobility (A), the time spent immobile (B) or the time spent in swimming (C). Interestingly, 
ARTH animals injected with AMI increased the time spent climbing (D) but only when 
compared with SHAM treated animals. Additionally, note that following AMI treatment of 
ARTH animals, no differences were observed with the SHAM group treated with SAL in the 
latency to immobility (A), total immobility (B) and time spent climbing (D). Results are 
expressed as Mean+SEM (n=8 per group). *P<0.05, **P<0.01. 
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